Vyne Therapeutics Inc
VYNE0.586USD
+0.001+0.21%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
18.62MMarket Cap
LossP/E TTM
More Details of Vyne Therapeutics Inc Company
VYNE Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need. Its lead program is repibresib gel (also known as VYN201), a topically administered, small-molecule pan-BD bromodomain and extra-terminal (BET) inhibitor designed as a soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways while providing low systemic exposure. Its second program is VYN202, an oral, small-molecule BD2-selective BET inhibitor. The Company has rights to research, develop and commercialize products containing BET inhibitor compounds for the treatment of any disease, disorder or condition in humans. Utilizing its InhiBET platform and through its preclinical and clinical activities, the Company is evaluating the impact that BET inhibitor compounds have on regulating pro-inflammatory cytokines.
Vyne Therapeutics Inc Info
Ticker SymbolVYNE
Company nameVyne Therapeutics Inc
IPO dateJan 25, 2018
CEODomzalski (David)
Number of employees13
Security typeOrdinary Share
Fiscal year-endJan 25
Address685 Route 202/206 N., Suite 301
CityBRIDGEWATER
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code08807
Phone18007757936
Websitehttps://vynetherapeutics.com/
Ticker SymbolVYNE
IPO dateJan 25, 2018
CEODomzalski (David)
Company Executives of Vyne Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Tyler Zeronda
Mr. Tyler Zeronda
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
112.77K
-2.94%
Ms. Mutya Fonte Harsch, J.D.
Ms. Mutya Fonte Harsch, J.D.
Chief Legal Officer, General Counsel, Secretary
Chief Legal Officer, General Counsel, Secretary
54.74K
+41.39%
Mr. Patrick G. Lepore
Mr. Patrick G. Lepore
Lead Independent Director
Lead Independent Director
51.47K
--
Dr. Iain Stuart, Ph.D.
Dr. Iain Stuart, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
44.30K
+57.33%
Mr. Steven L. Basta
Mr. Steven L. Basta
Independent Director
Independent Director
7.45K
--
Ms. Sharon Barbari
Ms. Sharon Barbari
Independent Director
Independent Director
--
--
Mr. David Domzalski
Mr. David Domzalski
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Elisabeth A. Sandoval Little
Ms. Elisabeth A. Sandoval Little
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Tyler Zeronda
Mr. Tyler Zeronda
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
112.77K
-2.94%
Ms. Mutya Fonte Harsch, J.D.
Ms. Mutya Fonte Harsch, J.D.
Chief Legal Officer, General Counsel, Secretary
Chief Legal Officer, General Counsel, Secretary
54.74K
+41.39%
Mr. Patrick G. Lepore
Mr. Patrick G. Lepore
Lead Independent Director
Lead Independent Director
51.47K
--
Dr. Iain Stuart, Ph.D.
Dr. Iain Stuart, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
44.30K
+57.33%
Mr. Steven L. Basta
Mr. Steven L. Basta
Independent Director
Independent Director
7.45K
--
Ms. Sharon Barbari
Ms. Sharon Barbari
Independent Director
Independent Director
--
--
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2024
FY2023
FY2022
FY2021
FY2020
By BusinessUSD
Name
Revenue
Proportion
Royalty revenues
501.00K
0.00%
Relevant data have not been disclosed by the company yet.
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Royalty revenues
501.00K
0.00%
Shareholding Stats
Updated: Tue, Nov 18
Updated: Tue, Nov 18
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Access Industries, Inc.
3.35%
Baker Bros. Advisors LP
2.56%
Delaware Street Capital, L.L.C.
2.09%
Acorn Capital Advisors, LLC
1.76%
Shay Capital LLC
1.48%
Other
88.75%
Shareholders
Shareholders
Proportion
Access Industries, Inc.
3.35%
Baker Bros. Advisors LP
2.56%
Delaware Street Capital, L.L.C.
2.09%
Acorn Capital Advisors, LLC
1.76%
Shay Capital LLC
1.48%
Other
88.75%
Shareholder Types
Shareholders
Proportion
Hedge Fund
8.41%
Corporation
3.35%
Investment Advisor
2.99%
Investment Advisor/Hedge Fund
2.19%
Individual Investor
1.31%
Research Firm
0.45%
Other
81.29%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
84
8.51M
25.77%
-898.65K
2025Q2
84
9.46M
56.76%
-1.30M
2025Q1
81
9.36M
56.20%
-1.38M
2024Q4
92
9.37M
63.49%
-533.87K
2024Q3
88
8.98M
61.30%
-594.32K
2024Q2
89
9.65M
66.73%
+287.65K
2024Q1
92
9.64M
67.66%
+101.95K
2023Q4
101
10.22M
72.71%
+4.63M
2023Q3
117
471.27K
14.37%
-340.06K
2023Q2
135
501.83K
15.37%
-314.68K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Access Industries, Inc.
1.12M
4.38%
--
--
Feb 14, 2025
Delaware Street Capital, L.L.C.
696.47K
2.73%
--
--
Sep 30, 2024
Acorn Capital Advisors, LLC
736.57K
2.89%
-49.37K
-6.28%
Jun 30, 2025
Ikarian Capital LLC
290.00K
1.14%
+290.00K
--
Jun 30, 2025
The Vanguard Group, Inc.
496.30K
1.95%
+20.65K
+4.34%
Jun 30, 2025
Domzalski (David T)
107.13K
0.42%
-12.68K
-10.58%
Sep 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Feb 10, 2023
Merger
18→1
Feb 10, 2023
Merger
18→1
Feb 10, 2023
Merger
18→1
Feb 10, 2023
Merger
18→1
Feb 12, 2021
Merger
4→1
Feb 12, 2021
Merger
4→1
Date
Type
Ratio
Feb 10, 2023
Merger
18→1
Feb 10, 2023
Merger
18→1
Feb 10, 2023
Merger
18→1
Feb 10, 2023
Merger
18→1
Feb 12, 2021
Merger
4→1
Feb 12, 2021
Merger
4→1
Feb 12, 2021
Merger
4→1
Feb 12, 2021
Merger
4→1
FAQs
Who are the top five shareholders of Vyne Therapeutics Inc?
The top five shareholders of Vyne Therapeutics Inc are:
Access Industries, Inc. holds 1.12M shares, accounting for 4.38% of the total shares.
Delaware Street Capital, L.L.C. holds 696.47K shares, accounting for 2.73% of the total shares.
Acorn Capital Advisors, LLC holds 736.57K shares, accounting for 2.89% of the total shares.
Ikarian Capital LLC holds 290.00K shares, accounting for 1.14% of the total shares.
The Vanguard Group, Inc. holds 496.30K shares, accounting for 1.95% of the total shares.
Access Industries, Inc. holds 1.12M shares, accounting for 4.38% of the total shares.
Delaware Street Capital, L.L.C. holds 696.47K shares, accounting for 2.73% of the total shares.
Acorn Capital Advisors, LLC holds 736.57K shares, accounting for 2.89% of the total shares.
Ikarian Capital LLC holds 290.00K shares, accounting for 1.14% of the total shares.
The Vanguard Group, Inc. holds 496.30K shares, accounting for 1.95% of the total shares.
What are the top three shareholder types of Vyne Therapeutics Inc?
The top three shareholder types of Vyne Therapeutics Inc are:
Access Industries, Inc.
Baker Bros. Advisors LP
Delaware Street Capital, L.L.C.
Access Industries, Inc.
Baker Bros. Advisors LP
Delaware Street Capital, L.L.C.
How many institutions hold shares of Vyne Therapeutics Inc (VYNE)?
As of 2025Q3, 84 institutions hold shares of Vyne Therapeutics Inc, with a combined market value of approximately 8.51M, accounting for 25.77% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -30.99%.
What is the biggest source of revenue for Vyne Therapeutics Inc?
In FY2024, the Royalty revenues business generated the highest revenue for Vyne Therapeutics Inc, amounting to 501.00K and accounting for --% of total revenue.
